Literature DB >> 21960356

Detailed dosimetric evaluation of intensity-modulated radiation therapy plans created for stage C prostate cancer based on a planning protocol.

Yoshiki Norihisa1, Takashi Mizowaki, Kenji Takayama, Yuki Miyabe, Kiyotomo Matsugi, Yukinori Matsuo, Masaru Narabayashi, Katsuyuki Sakanaka, Akira Nakamura, Yasushi Nagata, Masahiro Hiraoka.   

Abstract

BACKGROUND: Intensity-modulated radiation therapy (IMRT) has been employed as a precision radiation therapy with higher conformity to the target. Although clinical outcomes have been reported for many investigations, detailed treatment planning results have not been mentioned to date. The aim of this study was to evaluate the dose specifications of our IMRT treatment plans for locally advanced prostate cancer.
METHODS: Seventy-seven clinically applied IMRT plans treated between September 2003 and December 2005, in which patients were irradiated with 78 Gy in the prone position, were retrospectively analyzed. Dosimetric data output from dose volume histograms were evaluated in detail.
RESULTS: The mean dose ± standard deviation, homogeneity index, and conformity index to the planning target volume (PTV) were 78.3 ± 0.7 Gy (100.4 ± 0.9%), 13.7 ± 3.0, and 0.83 ± 0.04, respectively. For the clinical target volume, the mean dose was 80.3 ± 0.7 Gy (102.9 ± 0.9%).The V40, V60, and V70 Gy of the rectal wall were 58.3 ± 2.8, 29.6 ± 2.7, and 15.2 ± 3.0%, respectively. Planning difficulties were encountered in patients whose bowels were displaced downward, as constraints imposed by the bowel position altered the dose index of the PTV. In many cases, additional bowel optimization parameters were required to satisfy constraints for organs at risk. However, major deviation could be avoided by inverse planning with computer optimization.
CONCLUSION: IMRT allowed the creation of acceptable and practical treatment plans for locally advanced prostate cancer. Reports regarding detailed dosimetric evaluations are mandatory for interpreting clinical outcomes in the future.

Entities:  

Mesh:

Year:  2011        PMID: 21960356     DOI: 10.1007/s10147-011-0324-1

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  27 in total

Review 1.  Radiotherapy for nasopharyngeal carcinoma--transition from two-dimensional to three-dimensional methods.

Authors:  Peter M L Teo; Brigette B Y Ma; Anthony T C Chan
Journal:  Radiother Oncol       Date:  2004-11       Impact factor: 6.280

Review 2.  Advances in image-guided radiation therapy.

Authors:  Laura A Dawson; David A Jaffray
Journal:  J Clin Oncol       Date:  2007-03-10       Impact factor: 44.544

3.  A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate.

Authors:  A van't Riet; A C Mak; M A Moerland; L H Elders; W van der Zee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-02-01       Impact factor: 7.038

4.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

Authors:  M J Zelefsky; Z Fuks; M Hunt; H J Lee; D Lombardi; C C Ling; V E Reuter; E S Venkatraman; S A Leibel
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

5.  Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies.

Authors:  Arno J Mundt; Anthony E Lujan; Jacob Rotmensch; Steven E Waggoner; S Diane Yamada; Gini Fleming; John C Roeske
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-04-01       Impact factor: 7.038

6.  Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer.

Authors:  M J Zelefsky; Z Fuks; L Happersett; H J Lee; C C Ling; C M Burman; M Hunt; T Wolfe; E S Venkatraman; A Jackson; M Skwarchuk; S A Leibel
Journal:  Radiother Oncol       Date:  2000-06       Impact factor: 6.280

7.  Dosimetric and anatomic indicators of late rectal toxicity after high-dose intensity modulated radiation therapy for prostate cancer.

Authors:  Reshma Munbodh; Andrew Jackson; Joseph Bauer; C Ross Schmidtlein; Michael J Zelefsky
Journal:  Med Phys       Date:  2008-05       Impact factor: 4.071

8.  Planning target volume margins for prostate radiotherapy using daily electronic portal imaging and implanted fiducial markers.

Authors:  David Skarsgard; Pat Cadman; Ali El-Gayed; Robert Pearcey; Patricia Tai; Nadeem Pervez; Jackson Wu
Journal:  Radiat Oncol       Date:  2010-06-10       Impact factor: 3.481

9.  Intensity-modulated radiation therapy dose prescription, recording, and delivery: patterns of variability among institutions and treatment planning systems.

Authors:  Indra J Das; Chee-Wai Cheng; Kashmiri L Chopra; Raj K Mitra; Shiv P Srivastava; Eli Glatstein
Journal:  J Natl Cancer Inst       Date:  2008-02-26       Impact factor: 13.506

10.  Intracranial germinoma: on whole-ventricular irradiation.

Authors:  David Roberge; Larry E Kun; Carolyn R Freeman
Journal:  Pediatr Blood Cancer       Date:  2005-04       Impact factor: 3.167

View more
  12 in total

1.  Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer.

Authors:  Takashi Mizowaki; Yoshiki Norihisa; Kenji Takayama; Itaru Ikeda; Haruo Inokuchi; Kiyonao Nakamura; Tomomi Kamba; Takahiro Inoue; Toshiyuki Kamoto; Osamu Ogawa; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2016-02-03       Impact factor: 3.402

2.  Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance.

Authors:  Kiyonao Nakamura; Takashi Mizowaki; Haruo Inokuchi; Itaru Ikeda; Takahiro Inoue; Tomomi Kamba; Osamu Ogawa; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2017-07-29       Impact factor: 3.402

3.  Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.

Authors:  Takashi Mizowaki; Yoshiki Norihisa; Kenji Takayama; Itaru Ikeda; Haruo Inokuchi; Kiyonao Nakamura; Tomomi Kamba; Takahiro Inoue; Toshiyuki Kamoto; Osamu Ogawa; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2015-07-04       Impact factor: 3.402

4.  Clinical effect of multileaf collimator width on the incidence of late rectal bleeding after high-dose intensity-modulated radiotherapy for localized prostate carcinoma.

Authors:  Haruo Inokuchi; Takashi Mizowaki; Yoshiki Norihisa; Kenji Takayama; Itaru Ikeda; Kiyonao Nakamura; Mitsuhiro Nakamura; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2015-07-12       Impact factor: 3.402

5.  Intensity-modulated radiation therapy for prostate cancer after rectal surgery: a single hospital long-term safety analysis.

Authors:  Shuang Zhang; Kiyonao Nakamura; Rihito Aizawa; Shusuke Akamatsu; Takashi Mizowaki
Journal:  Int J Clin Oncol       Date:  2022-02-05       Impact factor: 3.402

6.  Correlation between urinary dose and delayed radiation cystitis after 78 Gy intensity-modulated radiotherapy for high-risk prostate cancer: A 10-year follow-up study of genitourinary toxicity in clinical practice.

Authors:  Haruo Inokuchi; Takashi Mizowaki; Yoshiki Norihisa; Kenji Takayama; Itaru Ikeda; Kiyonao Nakamura; Masahiro Hiraoka
Journal:  Clin Transl Radiat Oncol       Date:  2017-10-10

7.  Performance evaluation of a newly developed three-dimensional model-based global-to-local registration in prostate cancer.

Authors:  Mitsuhiro Nakamura; Megumi Nakao; Hideaki Hirashima; Hiraku Iramina; Takashi Mizowaki
Journal:  J Radiat Res       Date:  2019-10-23       Impact factor: 2.724

8.  Surveillance on interfacility differences in dose-prescription policy of intensity-modulated radiation therapy plans for prostate cancer.

Authors:  Takashi Mizowaki; Kazuo Hatano; Masahiro Hiraoka
Journal:  J Radiat Res       Date:  2012-06-06       Impact factor: 2.724

9.  Assessment of interfractional prostate motion in patients immobilized in the prone position using a thermoplastic shell.

Authors:  Itaru Ikeda; Takashi Mizowaki; Yohei Sawada; Manabu Nakata; Yoshiki Norihisa; Masakazu Ogura; Masahiro Hiraoka
Journal:  J Radiat Res       Date:  2013-07-16       Impact factor: 2.724

10.  A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer.

Authors:  Kiyonao Nakamura; Itaru Ikeda; Haruo Inokuchi; Kenji Takayama; Takahiro Inoue; Tomomi Kamba; Osamu Ogawa; Masahiro Hiraoka; Takashi Mizowaki
Journal:  J Radiat Res       Date:  2018-09-01       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.